In this podcast, Jennifer Curtis and David Jackson share valuable insights on global commercial excellence. They highlight strategies to optimize product launches and maximize revenue potential based on recent research conducted by ZS on the top 25 pharma companies.Hosted by: Jennifer CurtisProduced by: Matilda Males & Sophie McManusFeaturing: Davi…

In this episode, ZS leaders Jennifer Curtis, Pranav Srivastava and Surbhi Puri discuss customer experience in cell and gene therapy, drawing on recent ZS patient experience study outcomes.Hosted by: Jennifer CurtisProduced by: Matilda Males & Sophie McManusFeaturing: Pranav Srivastava and Surbhi Puri…

Jennifer Curtis discusses with Cody Powers and Nan Wang their latest research on how to drive stronger global strategy, focusing on the trends in in early- and late-stage pharma acquisitions.Hosted by: Jennifer CurtisProduced by: Matilda Males and Sophie McManusFeaturing: Nan Wang and Cody PowersΑπό τον ZS

When most global pharmaceutical launches are as likely to underperform as overperform, how can leaders ensure they prepare their organizations for success? On this episode of Inside Global Pharma, ZS leaders Jennifer Curtis and Maria Whitman share their perspectives on the next era of global launch and where leaders should be investing to set up th…

Our latest episode on Oncology Portfolio Strategy features Josh Hattem sharing insights into the oncology therapeutic area and implications of different customer lenses on portfolio design and strategy. This episode builds on concepts addressed in a previous Inside Global Pharma episode, The Value of Focus.Hosted by: Jennifer CurtisProduced by: Mat…

Jennifer Curtis and Ben Hohn discuss trends in emerging pharma commercialization.Hosted by: Jennifer CurtisProduced by: Matilda MalesFeaturing: Ben HohnΑπό τον ZS

Jennifer Curtis, Tina Shepley and Hensley Evans discuss the importance of patient centricity in market shaping for a successful product launch.Hosted by: Jennifer CurtisProduced by: Matilda MalesFeaturing: Hensley Evans and Tina ShepleyΑπό τον ZS

Jennifer Curtis and Jeffrey Moore discuss recent ZS insights and trends in #customerengagementHosted by: Jennifer CurtisProduced by: Matilda MalesFeaturing: Jeffrey MooreΑπό τον ZS

The road to commercializing cell and gene therapies was long, but during the last years we have observed strong market growth and a very crowded pipeline. In this episode, we discuss more challenges and what it takes to successfully launch and commercialize these advanced therapies.Hosted by: Jennifer CurtisProduced by: Matilda MalesFeaturing: Sank…

In light of World AIDS Day 2021, in this episode of ‘Inside Global Pharma’ we focus on the journey to eradicating AIDS and discuss themes of inequality today and how they can be managed.Hosted by: Jennifer CurtisProduced by: Matilda Males and Sophie McManusFeaturing: Mark Saunders and Bill CoyleΑπό τον ZS

We immersed ourselves in R&D to discuss what drives clinical trial success beyond the science alone. Join us to learn what it means to be human-centric in the context of clinical trials, and how human-centric principles and cognitive science can aid trial recruitment and execution.Hosted by: Jennifer CurtisProduced by: Matilda Males and Sophie McMa…

In this episode we are exploring the role of medical affairs in shaping stakeholder engagement strategies across both traditional and digital channels and what this means for the future of medical affairs.Hosted by: Jennifer CurtisProduced by: Matilda MalesFeaturing: Bora Erdemli and Sarah JarvisΑπό τον ZS

Customer engagement has been a hot topic across pharma med tech companies, even before the pandemic. In this episode, we discuss the future of customer engagement and how can companies deliver consistent, relevant, and positive experience in digital, in-person and hybrid world.Hosted by: Jennifer CurtisProduced by: Matilda MalesFeaturing: Jude Konz…

In this episode, our guest is Josh Hattem discussing insights from recent research on the value of focus in portfolio strategy for biopharmaceutical companies. Highlights from the episode include:- Defining what is a portfolio strategy within a biopharmaceutical company- Why focus can provide a competitive edge but companies often fail to maximize …

COVID-19 has pushed the idea of scenario planning to the forefront. It is becoming increasingly important to be able to anticipate and plan for the unexpected by looking at the extremes, and how they could change the business. In this episode we focus on oncology and discuss three different worlds that could emerge in the future and implications on…

Cancer has been progressively redefined over the past 20 years. One of the most active pipelines is immunotherapy, with almost 300 molecules in phase one or phase two trials. In this episode we are discussing if existing immunotherapies have lived up to the expectations and what will drive success for the next wave of products in this evolving mark…

COVID-19 has accelerated many trends that were only starting to emerge in healthcare before 2020. It led to an inflection point, bringing in new opportunities and challenges in how pharma and medtech companies serve patients and other customers. Here, we set to explore COVID-19 not just as a unique event and implications specific to it, but more as…

Patient centricity is a topic that has been floating around healthcare organizations for the better part of the last decade. Most healthcare companies have something about patients in their mission statement or vision. However, although the patients are the ultimate customers in the healthcare landscape, they may not always be in the forefront. In …

The oncology pharmaceutical landscape is exploding – both in revenue and competition. Integrated, customer-centric brand strategies provide an opportunity to stand out from the competition by delivering more customer value. Our host, Jennifer Curtis, a leader in our European Marketing Practice, speaks with leaders in ZS’ oncology, marketing and mar…

Over the last decade the combination of high unmet patient need and revenue potential has resulted in companies of all sizes moving into the Oncology space. Now competition is fierce and the pathway to success has many obstacles. There are more and more “me-too”, less clinically differentiated assets competing the same space with high prices. So, w…